







Nouvelles options dans le traitement des lésions calcifiées


Une lésion idéale pour la Lithotripsie intra coronaire

*B.Honton
Clinique Pasteur
Toulouse – France*

Mécanisme d'action de l'IVL



Mécanisme d'action de l'IVL



Fractures multiplanes / longitudinales dans la plaque calcique
Absence de production de débris

Monsieur C, 65 ans

D2 – HTA – Obésité (IMC à 31)

Angor d'effort – Ischémie inférieure scintigraphique : 15%





Sténose critique et focale de la CD3

Monsieur C, 65 ans




Tortuosité de la CD2

Monsieur C, 65 ans




Calcifications massives
et circomférentielles

Monsieur C, 65 ans



Predilatation NC 3.5x20 mm - 18 ATM

Monsieur C, 65 ans




Buddy Wire / Progression Shockwave C2 catheter 4x12 mm

Monsieur C, 65 ans



Premier cycle

60 impulsions : 5-10% sténose résiduelle



Sixième cycle

Monsieur C, 65 ans







Contrôle angiographique post IVL

26-27-28
JANVIER
2022



Monsieur C, 65 ans



Monsieur C, 65 ans

Franchissement DES 4 x 34 mm

Post dilatation au ballon NC de 4 mm - 22 ATM




Disrupt Clinical Program

	Disrupt CAD I	Disrupt CAD II	Disrupt CAD III	Disrupt CAD IV
Status	Enrollment completed	Enrollment completed	Enrollment completed	Enrollment completed
Study design	Single arm, safety & feasibility	Single arm, post-market, safety & effectiveness	Single arm, IDE, safety & effectiveness	Single arm, pre-market safety & effectiveness
# of patients	60	120	384	64
# of sites	7	15	47	8
Regions	AU, EU	EU	US, EU	Japan

Published	Circulation 2019	Circ Interv 2019	JACC 2020	Circulation Journal 2021
-----------	------------------	------------------	-----------	--------------------------

Disrupt CAD III : Flow Chart




*Kereiakes D. Am Heart J 2020;225:10-18

[†]Radio-opacities both sides of vessel $\geq 15\text{ mm}$ length by angiography or calcium angle $\geq 270^\circ$ by OCT or IVUS




Disrupt CAD III : 12 month FU

Overall MACE



Disrupt CAD III : 12 month FU

MACE distribution




at risk 384 377 377 372 372 384 377 364 355 289 384 354 344 339 336

ID-TLR	1.3%	4.3%
Stent thrombosis (definite or probable)*	0.8%	1.1%



Monsieur B, 87 ans

SCA NSTEMI – Akinésie inférieure – Tropo à 4186 ng/ml
ECG : FA - electroentraîné non contributif
HTA – Dyslipidémie





Occlusion / Sténose critique CD2

Monsieur B, 87 ans



Sténose critique TCG MEDINA 1-1-1


Monsieur B, 87 ans – Angioplastie TCG



26-27-28
JANVIER
2022




Monsieur B, 87 ans – Angioplastie TCG




Monsieur B, 87 ans


Ballon SW 4x12 mm
5s inflation



20 pulses



60 pulses




80 pulses

26-27-28
JANVIER
2022



Monsieur B, 87 ans – Angioplastie TCG




Kissing avec ballon de 3.5 x 20 mm

26-27-28
JANVIER
2022





Monsieur B, 87 ans – Angioplastie TCG



Stent de 3.5 x 24 mm – Crush à 5 mmm

Monsieur B, 87 ans – Angioplastie TCG




Stent IVA de 3.5 x 24 mm – POT à 6 mmm

26-27-28
JANVIER
2022



Monsieur B, 87 ans – Angioplastie TCG





	CAD I	CAD II	CAD III	CAD IV	Pooled
 Enrollment MARSEILLE	Dec 2015 – Sep 2016	May 2018 – Mar 2019	Jan 2019 – Mar 2020	Nov 2019 – Apr 2020	Dec 2015 – Apr 2020
Study design	Prospective, multi-center, single-arm				
ITT (N)	60	120	384	64	628
OCT Analysis* (N)	28	57	106	71	262
OCT core laboratory	Cardiovascular Research Foundation New York, NY				
Target lesions	Severely calcified*, de novo coronary artery lesions				
Target lesion RVD	2.5mm – 4.0mm				
Target lesion stenosis	≥50% and <100%	≥50% and <100%	≥70% and <100%	≥70% and <100%	≥70% and <100%
Publications	Circulation 2019	Circ Interv 2019	JACC 2020	Circulation Journal 2021	JACC Interv 2021

OCT Characterization of Eccentric Versus Concentric lesion

Disrupt CAD I-IV: OCT Sub-studies



Core Lab Analysis	≤ 180° N=56	181° - 270° N=56	271° - 359° N=51	360° N=66	P value
Minimum lumen area, mm ²	2.0 ± 1.1	2.1 ± 1.0	2.0 ± 0.8	2.1 ± 0.9	0.85
Area stenosis, %	72.4 ± 10.5	70.1 ± 11.2	72.7 ± 10.3	73.1 ± 12.5	0.24
Max continuous calcium arc*, °	131.1 ± 30.4	225.3 ± 27.3	309.3 ± 23.6	360.0 ± 0.0	<0.0001
Calcium index, ° × mm	1660 ± 803	3069 ± 1074	3794 ± 1423	5522 ± 2291	<0.0001
Max calcium thickness, mm	0.93 ± 0.27	0.92 ± 0.21	1.01 ± 0.27	0.97 ± 0.25	0.21
Min calcium thickness, mm	0.41 ± 0.13	0.35 ± 0.13	0.28 ± 0.14	0.27 ± 0.13	<0.0001

IVL dans les lésions excentriques




Electrodes further from calcified root
Lost of the spallation

Consistent Outcomes in Eccentric and Concentric Calcium Disrupt CAD I-IV: OCT Sub-studies



Consistent Outcomes in Eccentric and Concentric Calcium Disrupt CAD I-IV: OCT Sub-studies





REGISTRE NATIONAL FRANCE LILI LithopLastie Intracoronaire

GACI

Le registre France LILI, dont la SFC est le Promoteur, a pour objectif d'évaluer la sécurité et les performances du système de Lithotripsie coronaire C2 Shockwave Medical® (IVL), Inc. dans l'angioplastie coronaire chez des patients « tout venants » en France.

Critère composite Target Vessel Failure (TVF) à 1 an :

- Décès d'origine cardiaque
- Infarctus du myocarde selon la 4eme définition universelle de l'infarctus du myocarde (sauf si l'infarctus est clairement attribuable à un vaisseau non-cible)
- Revascularisation du vaisseau cible (TVR)
- 12 mois d'inclusion à partir du 16/11/2021 + 12 mois de suivi par patient

45 patients / 500 – 12 centres actifs



HOT TOPIC



ÉVALUER LES TECHNOLOGIES DE SANTÉ

**AVIS SUR LES
DISPOSITIFS
MÉDICAUX**

C2 IVL CATHETER

Cathéter du système de lithotripsie intravasculaire (ou IVL) coronaire

Inscription

Adopté par la Commission nationale d'évaluation des dispositifs médicaux et des technologies de santé le 18 janvier 2022